pages_aktie_[isin]_directordealings_0
components_InsiderTable_9
Esperion Therapeutics
pages_aktie_[isin]_directordealings_2
pages_insiderkaeufe_[isin]__0 pages_insiderkaeufe_[isin]__1pages_insiderkaeufe_[isin]__2 pages_insiderkaeufe_[isin]__3pages_insiderkaeufe_[isin]__4 pages_insiderkaeufe_[isin]__5pages_aktie_[isin]_directordealings_3
Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets.
components_InsiderFAQ__11
components_InsiderFAQ__0
components_InsiderFAQ__2
components_InsiderFAQ__4
components_InsiderFAQ__5
components_InsiderFAQ__7
components_InsiderFAQ__9
components_InsiderArticle__0
components_InsiderArticle__1
components_InsiderArticle__5
components_InsiderArticle__8
components_InsiderArticle__9
components_InsiderArticle__12
components_InsiderArticle__13
components_InsiderArticle__16
components_InsiderArticle__17
components_InsiderArticle__20
components_InsiderArticle__22
components_InsiderArticle__25
components_InsiderArticle__28
components_InsiderArticle__31
components_InsiderArticle__32
components_InsiderArticle__34
components_InsiderArticle__36
components_InsiderArticle__37
components_InsiderArticle__38
components_InsiderArticle__40
components_InsiderArticle__41 components_InsiderArticle__42 components_InsiderArticle__43 components_InsiderArticle__44 components_InsiderArticle__45
- components_InsiderArticle__48
- components_InsiderArticle__49
components_InsiderArticle__50
components_InsiderArticle__51
components_InsiderArticle__54
components_InsiderArticle__55
components_InsiderArticle__58
components_InsiderArticle__59
- components_InsiderArticle__61
- components_InsiderArticle__62
- components_InsiderArticle__63
- components_InsiderArticle__64
- components_InsiderArticle__65
- components_InsiderArticle__66
components_InsiderArticle__67
components_InsiderArticle__68
components_InsiderArticle__73
components_InsiderArticle__74
components_InsiderArticle__77
components_InsiderArticle__78
components_InsiderArticle__81
components_InsiderArticle__82
components_InsiderArticle__85
components_InsiderArticle__86 components_InsiderArticle__87. components_InsiderArticle__88
components_InsiderArticle__90
components_InsiderArticle__93
components_InsiderArticle__94
components_InsiderArticle__97
components_InsiderArticle__98
components_InsiderArticle__103
components_InsiderArticle__110
components_InsiderArticle__113
components_InsiderArticle__114
components_InsiderArticle__116
components_InsiderArticle__118 components_InsiderArticle__119 components_InsiderArticle__120
components_InsiderArticle__121
components_InsiderArticle__122
components_InsiderArticle__125
components_InsiderArticle__126
components_InsiderArticle__129
components_InsiderArticle__132
components_InsiderArticle__137
components_InsiderArticle__142
components_InsiderArticle__145
components_InsiderArticle__147
components_InsiderArticle__148
components_InsiderArticle__150
components_InsiderArticle__155
components_InsiderArticle__158
components_InsiderArticle__159
components_InsiderArticle__162
components_InsiderArticle__163
components_InsiderArticle__166
components_InsiderArticle__167
components_InsiderArticle__172
components_InsiderArticle__175
components_InsiderArticle__178
components_InsiderArticle__181
components_InsiderArticle__182
components_InsiderArticle__184
components_InsiderArticle__187
components_InsiderArticle__190
components_InsiderArticle__192
components_DirectorsDealingsText_5
components_InsiderArticle__196
components_InsiderArticle__197
components_InsiderArticle__199
components_InsiderArticle__200
components_InsiderArticle__203
components_InsiderArticle__206
components_InsiderArticle__209
components_InsiderArticle__212
components_InsiderArticle__215 components_DirectorsDealingsText_7 components_InsiderArticle__216 components_InsiderArticle__217